Clinical Trial

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-21
notable Trial sites expanded: 2 -> 10 locations 2026-04-21
Trial Details
NCT Number NCT07446439
Lead Sponsor Vanda Pharmaceuticals
Conditions Nausea and Vomiting, Obesity
Enrollment 280 participants
Start Date 2026-03-27
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-20